Milestone Pharma’s Next Big Move After FDA Nod

By Chris Lange Published Jul 23, 9:54AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares more than doubled on Thursday after the company announced a key clinical and regulatory update. The firm also announced a private placement offering to capitalize on this gain and shore up its balance sheet.

The U.S. Food and Drug Administration (FDA) outlined an efficient path to registration for the company’s etripamil nasal spray. Recent interactions have management optimistic. Also, this path to registration would eliminate the need to start a new Phase 3 study.

The FDA agreed with Milestone’s plan to modify the ongoing NODE-301B study, which is now known as the RAPID study, to highlight the unique pharmacology of etripamil, including a primary endpoint of time to conversion within 30 minutes. This study, along with the recently completed NODE-301 study, which also now will use a 30-minute endpoint, will serve to fulfill the efficacy requirements for a New Drug Application (NDA) for etripamil in paroxysmal supraventricular tachycardia.

Note that the etripamil nasal spray is the company’s investigational short-acting calcium channel blocker for patients with paroxysmal supraventricular tachycardia — in simpler words, an abnormal heart rhythm.

[nativounit]

At the same time, the company announced a private placement offering for $25 million with RTW Investments. Keep in mind that the company has a market cap of roughly $84 million, even after Thursday’s move.

The company expects that net proceeds from the private placement, along with current cash, cash equivalents and short-term investments, will be sufficient to fund planned operations through the second quarter of 2022.

Milestone Pharmaceuticals stock traded about 140% to $8.00 on Thursday, in a 52-week range of $1.69 to $24.01. The consensus price target is $4.00.

[recirclink id=725092][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.